Business

Mass. Movers

Insulet narrows loss in fourth quarter

An earlier version of Insulet’s OmniPod insulin pump.
An earlier version of Insulet’s OmniPod insulin pump.

Bedford’s Insulet Corp. said fourth-quarter 2013 revenue rose 19 percent to $68.5 million, compared to $57.8 million in the same period in 2012. Insulet said the revenue bump was a result of continued strong patient adoption of the OmniPod insulin pump in the United States and international markets. The company said its net loss was $2.5 million, or 4 cents per share, compared to a loss of $10.2 million, or 21 cents, in 2012. The results, however, beats analysts’ estimated loss of 9 cents.

Advertisement